Evidence map›Paper›PMID 29253067›Full record

ArticleAmerican journal of epidemiology2018

Testing Pneumonia Vaccines in the Elderly: Determining a Case Definition for Pneumococcal Pneumonia in the Absence of a Gold Standard.

Jukka Jokinen, Marja Snellman, Arto A Palmu, Annika Saukkoriipi, Vincent Verlant, Thierry Pascal, Jeanne-Marie Devaster, William P Hausdorff, Terhi M Kilpi

Open access · bronzeAbstract read
In one paragraph

Article in American journal of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. A New Approach for Classifying Fetal Growth Restriction.Epidemiology (Cambridge, Mass.) · 2021
    Article
  4. Culture of all sputum samples irrespective of quality adds value to the diagnosis of pneumococcal community-acquired pneumonia in the elderly.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jukka JokinenDepartment of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
Marja SnellmanDepartment of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
Arto A PalmuDepartment of Public Health Solutions, National Institute for Health and Welfare, Tampere, Finland.
Annika SaukkoriipiDepartment of Public Health Solutions, National Institute for Health and Welfare, Oulu, Finland.
Vincent VerlantGSK, Wavre, Belgium.
Thierry PascalGSK, Wavre, Belgium.
Jeanne-Marie DevasterGSK, Wavre, Belgium.
William P HausdorffGSK, Wavre, Belgium.
Terhi M KilpiDepartment of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
Finnish Institute for Health and Welfare · FIGlaxoSmithKline (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical assessments of vaccines to prevent pneumococcal community-acquired pneumonia (CAP) require sensitive and specific case definitions, but there is no gold standard diagnostic test. To develop a new case definition suitable for vaccine efficacy studies, we applied latent class analysis (LCA) to the results from 7 diagnostic tests for pneumococcal etiology on clinical specimens from 323 elderly persons with radiologically confirmed pneumonia enrolled in the Finnish Community-Acquired Pneumonia Epidemiology study during 2005-2007. Compared with the conventional use of LCA, which is mainly to determine sensitivities and specificities of different tests, we instead used LCA as an appropriate instrument to predict the probability of pneumococcal etiology for each CAP case based on individual test profiles, and we used the predictions to minimize the sample size that would be needed for a vaccine efficacy trial. When compared with the conventional laboratory criteria of encapsulated pneumococci in culture, in blood culture or high-quality sputum culture, or urine antigen positivity, our optimized case definition for pneumococcal CAP resulted in a trial sample size that was almost 20,000 subjects smaller. We believe that the novel application of LCA detailed here to determine a case definition for pneumococcal CAP could also be similarly applied to other diseases without a gold standard.

Indexed as

AgedAged, 80 and overBacteriological TechniquesCommunity-Acquired InfectionsFemaleFinlandHumansLatent Class AnalysisMalePneumococcal VaccinesPneumonia, PneumococcalSensitivity and SpecificityStreptococcus pneumoniaeTreatment OutcomePneumococcal Vaccines

Identifiers

PMID29253067
PMCPMC5982705
OpenAlexW2772812348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.